Mark Day
Directeur/Bestuurslid bij Aeromics, Inc.
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Deborah Rathjen | M | - | 7 jaar | |
| Jeffrey P. Draime | M | 57 |
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 7 jaar |
| David Wurzer | M | 65 | 6 jaar | |
| Christopher Lowe | M | 56 | 7 jaar | |
| Makarand Jawadekar | M | 73 | 4 jaar | |
| John E. Curran | M | - | 6 jaar | |
| Theodore Rokita | M | 54 | 4 jaar | |
| Peter Longo | M | - |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 8 jaar |
| Peter C. Agre | M | - |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 5 jaar |
| Mario David Saltarelli | M | 63 | 6 jaar | |
| Thomas Zindrick | M | 65 |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 6 jaar |
| Dave Jenkins | M | - |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 5 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Robin Hutchison | M | 68 | 10 jaar | |
| Marc F. Pelletier | M | 53 |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 12 jaar |
| David Brennan | M | 70 | 7 jaar | |
| Stephen P. Squinto | M | 67 | 23 jaar | |
| Felix Baker | M | 55 | 6 jaar | |
| Mukund S. Kulkarni | M | 76 | 6 jaar | |
| Judith F. Dalling | F | 69 | 3 jaar | |
| J. Hutchison | M | 68 | 9 jaar | |
| Christopher Coughlin | M | 71 | 7 jaar | |
| H. Christian Fibiger | M | 80 | 7 jaar | |
| James Sapirstein | M | 63 | 2 jaar | |
| Gregory Gubitz | M | 66 | 5 jaar | |
| Nancy E. Stagliano | M | 57 | 2 jaar | |
| William Keller | M | 75 | 6 jaar | |
| Mahalakshmi Radhakrishnan | M | - | 1 jaar | |
| Max E. Link | M | 84 | 22 jaar | |
| M. Burns | F | 66 | 4 jaar | |
| Catherine London | F | - | - | |
| Terry Pearson | M | 78 | 9 jaar | |
| Ronald Erickson | M | 80 | 7 jaar | |
| Caroline Dircks | M | - | 2 jaar | |
| Doug Williams | M | - | - | |
| Caroline Hill | M | - | - | |
| Melissa Manno | F | - | 2 jaar | |
| Matthew Batters | M | 48 | 4 jaar | |
| Randy Teel | M | 45 | 2 jaar | |
| George Llado | M | 58 | - | |
| Brian Krex | M | 57 | 4 jaar | |
| Jens Renstrup | M | 59 | 3 jaar | |
| Thomas-Christian Mix | M | 57 | 2 jaar | |
| Mohammed Qatanani | M | 50 | 3 jaar | |
| John Tilton | M | 56 | 10 jaar | |
| Behrad Derakhshan | M | 44 | 2 jaar | |
| Lisa Trivison Beck | F | 62 | 3 jaar | |
| Martine Zimmermann | M | 55 | 7 jaar | |
| Paul R. McGuirk | M | 72 |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | 11 jaar |
| John Michael Hutchison | M | 80 | 6 jaar | |
| Jason Meyenburg | M | 47 | 13 jaar | |
| Edward Miller | M | 59 | 3 jaar | |
| James Engelhart | M | 60 | 2 jaar | |
| Saqib Islam | M | 54 | 3 jaar | |
| Dominique Monnet | M | 65 | 1 jaar | |
| Reinhard Gabathuler | M | - | - | |
| Henric Bjarke | M | 57 | 5 jaar | |
| F. Carsten Thiel | M | 61 | 3 jaar | |
| Stephanie Fagan | F | - | 2 jaar | |
| Paresh N. Soni | M | 63 | 2 jaar | |
| Bill Lundberg | M | 60 | 4 jaar | |
| Jeremy Springhorn | M | 61 | 9 jaar | |
| Jing Marantz | M | 59 | 2 jaar | |
| Joseph Newell | M | 54 | 2 jaar | |
| John V. W. Reynders | M | - | 6 jaar | |
| Julie O'Neill | F | 58 | 3 jaar | |
| Romesh R. Subramanian | M | 58 | 3 jaar | |
| Christine Antalik | F | 53 | 2 jaar | |
| Mittie Doyle | M | 59 | 3 jaar | |
| Radhika Tripuraneni | M | 44 | - | |
| Al Boyle | M | - | 6 jaar | |
| Derek Adams | M | 50 | 11 jaar | |
| Albert Paszek | M | - | 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 72 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
